Journals / Medeniyet Medical Journal / 2021 / Cilt: 36 - Sayı: 1

A Rare Cause of ST-Segment Elevation Myocardial Infarction in COVID-19: MINOCA Syndrome

COVID-19’da ST Segment Yükseklikli Miyokart İnfarktüsünün Nadir Bir Nedeni: MINOCA Sendromu

Pages
63–68
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

To explain these processes associated with MINOCA syndrome, further clinical trials are needed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Myocardial infarction with nonobstructive coronary arteries (MINOCA) is defined as having a stenosis of less than 50% or no stenosis in coronary angiography in a patient diagnosed with myocardial infarction.Because of its thrombogenic predisposition in COVID-19, the diagnosis of MINOCA syndrome is rarely thought in the patients with ST-segment elevation myocardial Infarction on electrocardiogram.
📊
Key Findings & Data:In this case report, we discuss a 47-year-old male patient diagnosed with MINOCA who was followed up with respiratory failure due to COVID-19 viral pneumonia in intensive care unit.
💡
Conclusion & Impact:To explain these processes associated with MINOCA syndrome, further clinical trials are needed.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Myocardial infarction with nonobstructive coronary arteries (MINOCA) is defined as having a stenosis of less than 50% or no stenosis in coronary angiography in a patient diagnosed with myocardial infarction.Because of its thrombogenic predisposition in COVID-19, the diagnosis of MINOCA syndrome is rarely thought in the patients with ST-segment elevation myocardial Infarction on electrocardiogram. In this case report, we discuss a 47-year-old male patient diagnosed with MINOCA who was followed up with respiratory failure due to COVID-19 viral pneumonia in intensive care unit. His 12-lead electrocardiogram showed “inferior STEMI”. A 30-40% stenosis was also shown in the midportion of left anterior descending artery in emergency coronary angiography. The patient had a normal computed tomographic pulmonary angiography and was discharged with a full recovery.MINOCA may be triggered by hyperinflammation or various processes due to COVID-19. To explain these processes associated with MINOCA syndrome, further clinical trials are needed.

Özet

Non-obstrüktif Koroner Arterlerle birlikte Miyokart İnfarktüsü (MINOCA), miyokard infarktüsü teşhisi konulan bir hastada koroner anjiyografide darlığın %50’den az olması veya dar olmaması olarak tanımlanır. COVID-19’daki büyük trombojenik yatkınlığı nedeniyle, elektrokardiyogram’da ST-elevasyonlu miyokard infarktüsü görülen hastalarda MINOCA sendromu tanısı nadiren düşünülür. Bu vaka sunumunda, yoğun bakım ünitesi’nde, COVID-19 viral pnömonisine bağlı solunum yetmezliği ile takip eden MINOCA tanısı almış 47 yaşında bir erkek hastayı tartışıyoruz. Hastanın 12-derivasyonlu elektrokardiyografisinde “inferiyor STEMI” vardı. Acil koroner anjiyografide de sol ön inen arter orta kısmında %30-40 darlık gösterildi. Bilgisayarlı tomografik pulmoner anjiyografisi normal olan hasta iyileşerek evine taburcu edildi. MINOCA, COVID-19’a bağlı olarak hiperinflamasyon veya çeşitli süreçlerle tetiklenebilir. MINOCA sendromuyla ilişkili bu süreçleri açıklamak için daha fazla klinik denemeye ihtiyaç vardır.

🔖

Cite This Article

EROĞLU, S. E., AKSEL, G., ADEMOĞLU, E., BAYRAM, S. (2022). A Rare Cause of ST-Segment Elevation Myocardial Infarction in COVID-19: MINOCA Syndrome. Medeniyet Medical Journal, Cilt: 36 - Sayı: 1, 63–68. https://ajindex.com/articles/579191

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Ali MAM, Spinler SA. COVID-19 and thrombosis: From bench to bedside. Trends Cardiovasc Med. 2020;31:143-60. [CrossRef] 2. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18:1421-4. [CrossRef] 3. Hippensteel JA, Burnham EL, Jolley SE. Prevalence of venous thromboembolism in critically ill patients with COVID-19. Br J Haematol. 2020;190:e134-7. [CrossRef] 4. Klok FA, Kruip MJHA, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020;191:148-50. [CrossRef] 5. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intens Care Med. 2020;46:1089-98. [CrossRef] 6. McFadyen JD, Stevens H, Peter K. The emerging threat of (micro) thrombosis in COVID-19 and its therapeutic implications. Circ Res. 2020;127:571-87. [CrossRef] 7. Abobaker A, Raba AA, Alzwi A. Extrapulmonary and atypical clinical presentations of COVID-19. J Med Virol. 2020;92:2458-64. [CrossRef] 8. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Circulation. 2018;138:e618-51. [CrossRef] 9. Bangalore S, Sharma A, Slotwiner A, et al. ST-segment elevation in patients with Covid-19 - a case series. N Engl J Med. 2020;382:2478-80. [CrossRef] 10. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14. [CrossRef] 11. Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and cardiovascular disease. Circulation. 2020;141:1648-55. [CrossRef] 12. Popovic B, Varlot J, Metzdorf PA, Jeulin H, Goehringer F, Camenzind E. Changes in characteristics and management among patients with ST-elevation myocardial infarction due to COVID-19 infection. Catheter Cardiovasc Interv. 2021;97:e319-26. [CrossRef] 13. Agewall S, Beltrame JF, Reynolds HR, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J. 2017;38:143-53. [CrossRef] 14. Polgreen LA, Riedle BN, Cavanaugh JE, et al. Estimated cardiac risk associated with macrolides and fluoroquinolones decreases substantially when adjusting for patient characteristics and comorbidities. J Am Heart Assoc. 2018;7:e008074. [